Complete clearance of EGFR mutations from plasma following osimertinib administration in advanced NSCLC has been shown to strongly predict PFS, objective response rate (ORR), and disease control rate (DCR) [52]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.